Jazz Pharmaceuticals (JAZZ) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Jazz Pharmaceuticals faces potential risks related to increasing scrutiny on diversity, equity, and inclusion (DEI) efforts, which are integral to its talent management strategy. The recent executive order from the U.S. President opposing DEI initiatives in the private sector exemplifies the growing challenge from activists and policymakers. This scrutiny could lead to litigation or investigations, potentially resulting in legal injunctions, financial penalties, or reputational damage. Additionally, failure to implement or be perceived as implementing effective DEI initiatives could hinder the company’s ability to attract and retain a diverse workforce.
The average JAZZ stock price target is $187.31, implying 29.92% upside potential.
To learn more about Jazz Pharmaceuticals’ risk factors, click here.